Xenetic Biosciences, Inc.

NasdaqCM:XBIO Stock Report

Market Cap: US$6.1m

Xenetic Biosciences Future Growth

Future criteria checks 2/6

Xenetic Biosciences's earnings are forecast to decline at 32.8% per annum while its annual revenue is expected to grow at 28.3% per year. EPS is expected to grow by 30% per annum.

Key information

-32.8%

Earnings growth rate

30.0%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate28.3%
Future return on equityn/a
Analyst coverage

Low

Last updated22 Mar 2024

Recent future growth updates

Recent updates

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Dec 15
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Dec 01
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Xenetic Biosciences reports Q2 results

Aug 12

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Aug 02

Xenetic inks clinical manufacturing contract with Catalent

Jul 07

Xenetic Biosciences reports Q3 results

Nov 13

Earnings and Revenue Growth Forecasts

NasdaqCM:XBIO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262-18N/AN/A1
12/31/20252-11N/AN/A1
12/31/20243-6N/AN/A1
12/31/20233-4-4-4N/A
9/30/20232-4-4-4N/A
6/30/20232-4-4-4N/A
3/31/20232-6-4-4N/A
12/31/20222-7-5-5N/A
9/30/20222-7-6-5N/A
6/30/20221-7-6-5N/A
3/31/20221-6-5-5N/A
12/31/20211-6-5-5N/A
9/30/20211-5-4-4N/A
6/30/20211-11-4-4N/A
3/31/20211-11-5-5N/A
12/31/20200-11-4-4N/A
9/30/20200-11-5-5N/A
6/30/20200-14-6-6N/A
3/31/20200-14-6-6N/A
12/31/20190-18-6-6N/A
9/30/2019N/A-19-6-6N/A
6/30/2019N/A-10-5-5N/A
3/31/2019N/A-11-6-6N/A
12/31/2018N/A-7-6-6N/A
9/30/20188-1-1-1N/A
6/30/20188-2-1-1N/A
3/31/20188-300N/A
12/31/20178-411N/A
9/30/20173-12N/A-8N/A
6/30/20173-13N/A-7N/A
3/31/20173-58N/A-7N/A
12/31/20163-58N/A-9N/A
9/30/2016N/A-57N/A-5N/A
6/30/2016N/A-60N/A-6N/A
3/31/2016N/A-14N/A-5N/A
12/31/2015N/A-13N/A-5N/A
9/30/2015N/A-13N/A-7N/A
6/30/2015N/A-11N/A-8N/A
3/31/2015N/A-13N/A-11N/A
12/31/2014N/A-14N/A-13N/A
9/30/2014N/A-14N/A-12N/A
6/30/2014N/A-13N/A-12N/A
3/31/20141-11N/A-9N/A
12/31/20131-9N/A-6N/A
9/30/20131-7N/A-5N/A
6/30/20131-6N/A-5N/A
3/31/20130-6N/A-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XBIO's revenue (28.3% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: XBIO's revenue (28.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XBIO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.